Gland Pharma Ltd (GLAND) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Gland Pharma enters the Q1 FY27 results season navigating a complex global supply chain, with persistent drug shortages in the U.S. market providing a tailwind for its core injectable business. Investors will be focused on whether the company can maintain its margin trajectory amidst rising solvent costs and how the currency tailwinds from a weaker rupee impact its reported revenue growth.

Gland Pharma Ltd Q1 Results Date and Time

The board is scheduled to meet on August 10, 2026, to consider the unaudited Q1 FY27 financial results.

The earnings call is scheduled for August 10, 2026, at 18:30 IST.

What to expect from Gland Pharma Ltd's Q1 FY27 results

Management has guided for 12%-13% constant currency revenue growth for FY27, a target characterized as conservative and low-risk based on products already approved or with tentative approvals. The company's base business is expected to track in-line with this guidance, supported by persistent U.S. drug shortages that have maintained demand for its injectable portfolio. While gross margins face pressure from a 200-300% surge in solvent and intermediate costs reported by industry peers, Gland's ~285-day raw material inventory buffer is expected to mitigate the immediate impact. The significant depreciation of the rupee against the USD and EUR through Q1 FY27 serves as a notable translation tailwind, likely boosting reported revenue and other income compared to the Q1 FY26 average exchange rate. Cenexi is expected to maintain its positive EBITDA trajectory, building on the three profitable quarters achieved in FY26, as it benefits from the absence of a planned summer shutdown this quarter.

Key Things To Watch

Performance vs Guidance Tracking: Monitoring progress against FY27 operational targets.

• Consolidated revenue growth 12%-13% constant currency — FY27 — Q1 data point will indicate if the quarterly run-rate is on path
• Base business revenue growth 12%-13% — FY27 — Assessing if base business ex-Cenexi matches the 12-13% target
• Cenexi EBITDA mid-single to high-single digit — FY27 — Checking if Cenexi maintained the positive EBITDA trajectory from FY26
• INR500 Cr capex for FY27 — FY27 — Q1 spend should be approximately 20-25% of annual guidance

Cenexi Operational Trajectory: Assessing the turnaround progress of the European subsidiary.

• Q1 FY27 revenue run-rate vs Q1 FY26 EUR 48 Mn baseline
• EBITDA margin progress toward the mid-single to high-single digit target

US Market & Sugammadex Launch: Evaluating the sustainability of US growth and early launch traction.

• Sustainability of Q4 FY26 26% YoY US growth vs one-time restocking effects
• Early traction disclosure for Sugammadex Injection following the July 29, 2026 Day-1 launch
• Competitive landscape update given the 3+ generic entrants within days of launch

Margin Sustainability & Capacity: Monitoring cost pass-through and infrastructure constraints.

• Base business Adj. EBITDA margin sustainability vs Q4 FY26 41% peak
• Impact of solvent cost pass-through pressure in Q1 vs deferred impact via inventory buffer
• Capacity utilization update for lyophilizers and liquid vials operating near 90% in FY26